Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...Further, the company said it is evaluating its entire acreage position in anticipation of an aggressive, multi-year drilling program beginning in the third quarter of 2010.
http://www.rttnews.com/ArticleView.aspx?Id=1255433
<<<The last sentence makes me feel better and may add here.>>>
Canadian Superior Energy Q4 Loss Widens
3/30/2010 10:39 AM ET
http://www.rttnews.com/ArticleView.aspx?Id=1255433
(RTTNews) - Diversified energy company Canadian Superior Energy Inc. (SNG.TO: News ,SNG: News ) reported Tuesday a wider loss for the fourth quarter, reflecting significant declines in commodity prices and production volumes.
For the fourth quarter, the Calgary, Alberta-based company's net loss widened to $63.9 million or $0.32 per share from $18.19 million or $0.11 per share in the previous year.
Petroleum and Natural Gas sales, net of transportation dropped 25% to $9.93 million from $13.21 million in the year-ago quarter.
The company noted that the decrease was mainly due to significant declines in commodity prices, natural declines in production volumes and the company's inability to tie-in the successful wells from the 2008 drilling program due to limited capital available during CCAA.
Average production of Natural Gas decreased to 14,428 mcf/d from 15,726 mcf/d in the previous year. Oil and NGL average production was 653 bbls/d, up from 599 bbls/d in the prior-year quarter.
Western Canada average daily production for the quarter averaged 3,058 boe/d.
Average selling price of Natural Gas declined to $4.82 per mcf from $7.22 per mcf in the previous year. Oil and NGL's average selling price increased to $56.73 per bbl from $50.25 per bbl reported a year ago.
Capital expenditures for the quarter were $19.36 million, down from $42.89 million reported in the preceding year. The company said capital expenditures planned for the balance of 2010 would be around $25 million with near-term focus on the Drumheller and Kaybob core areas.
For the full year, the company's net loss widened to $53.32 million or $0.30 per share from $23.76 million or $0.16 per share in the prior year. Petroleum and Natural Gas sales, net of transportation dropped 55% to $33.77 million from $74.46 million in the year 2008.
Marvin Chronister, chairman of the board said, "While the Company has been through a very difficult period during 2009, we believe it has emerged and continues to evolve as a much stronger company than it has ever been. We are aggressively pursuing our growth strategy and development of our assets. Therefore, we believe the best is still to come for our shareholders."
Further, the company said it is evaluating its entire acreage position in anticipation of an aggressive, multi-year drilling program beginning in the third quarter of 2010.
SNG closed Monday's regular trading at $0.56 on the AMEX, while SNG.TO ended at $0.59.
Canadian Superior Energy Reports Its Financial and Operating Results for the Quarter and Year Ended December 31, 2009
Date : 03/30/2010 @ 8:28AM
Source : MarketWire
Stock : Canadian Superior Energy Inc. (SNG)
http://ih.advfn.com/p.php?pid=nmona&cb=1269952574&article=42183803&symbol=T^SNG
Canadian Superior Energy Inc. ("Canadian Superior" or the "Company") (TSX: SNG) (NYSE Alternext US: SNG) announced today the release of its fourth quarter and year-end financial results for 2009. The "Management's Discussion and Analysis" and audited consolidated financial statements for the year ended December 31, 2009, can be viewed on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.
In addition Canadian Superior announced it has filed its statements of reserves data and other oil and gas information for the year ended December 31, 2009 (the "Statement of Reserves Data"), as mandated by National Instrument 51-101 - Standards of Disclosure for Oil and Gas Activities. The Statement of Reserves Data is included in the annual information form of Canadian Superior for the year ended December 31, 2009 (the "AIF"). Copies of Canadian Superior's AIF may be obtained on SEDAR.
Financial and Operating Highlights
- In September, 2009, the Company emerged from protection under the Companies' Creditors Arrangement Act (Canada) ("CCAA"). A new board of directors was appointed and the Company obtained a new $25 million line of credit which has since been increased to $40 million.
- In January 2010, the Company completed a private placement for gross proceeds of approximately $59.5 million and named James H.T. Riddell to the board of directors.
- Converted all the issued and outstanding Series A Preferred Shares for an equal number of Series B Preferred Shares and extended the redemption date from December 31, 2010 to December 31, 2011.
- In consideration of the current industry environment and market conditions, the Company announced in December 2009 that it relinquished its Mayflower and Marauder (Nova Scotia offshore exploration licenses 2406 and 2415). The Company did extend the Mariner Block (2409) until at least December 31, 2010.
- Effective January 1, 2010, the Company entered into a financial hedge whereby a Canadian chartered bank will cover 5500 GJ/day for a period January 1, 2010 to December 31, 2010at $5.50 CAD/GJ against AECO monthly average index.
- Western Canada average daily production for the fourth quarter averaged 3,058 boe/d compared to 2,548 boe/d for the previous quarter. On a full year basis, average daily production was 3,020 boe/d in 2009 compared to 3,442 boe/d in 2008. The year-over-year decrease in volumes is primarily due to natural declines combined with minimal capital expenditures in 2009 imposed during the period the Company was under CCAA protection.
- The Company's proved plus probable reserves were 9,907 MBOE at December 31, 2009 compared to 10,585 MBOE for the previous year. The reduction was due to lack of reserve replacement related to the lower capital expenditures in 2009.
- Petroleum and natural gas sales decreased from $74.5 million in 2008 to $33.7 million in 2009. The decrease is mainly due to significant declines in commodity prices , natural declines in production volumes in 2009 compared to 2008 and the Company's inability to tie-in the successful wells from the 2008 drilling program due to limited capital available during CCAA.
- The Company was forced to postpone the 2009 drilling program until the Company exited from CCAA protection. The Company drilled 13 gross exploration wells (11.4 net) during November and December 2009 which satisfied the flow through commitment. The Company has approximately 800 boe/d awaiting tie-in.
- The increased loss in 2009 of $(53.3) million compared to the loss of $(23.8) million in 2008 is primarily due to decline in natural gas prices, $18.8 million in restructuring costs related to the receivership of the Trinidad Block 5 (c) asset and CCAA proceedings, and the write-down of the Canadian petroleum and natural gas properties of $57.5 million. The write down was primarily related primarily to pricing and slightly lower proved reserves in 2009 compared to 2008. In addition, approximately $40 million of unproved properties were added to the full cost pool, including $20 million related to East Coast Canada.
- The Company is planning the Zarat North appraisal well to be drilled in Tunisia. The rig selection process is well underway and the Company expects to have a contract in place soon. It is currently anticipated the well will be completed by year end.
- Geotechnical work continues on the 5c Block offshore Trinidad. The Company, together with its' partner and operator BG, are working to determine the optimal appraisal and commercialization strategy for the block. It is currently anticipated that an appraisal well will be drilled later this year or early next year. With the respect to the MG Block, the Company has met with Petrotrin and the Ministry of Energy and has formally requested that our obligations be transferred to a less environmentally sensitive and more prospective area. While we are hopeful that our request will be granted, it is possible that in order to relinquish the block we will be required to pay some portion of the performance security referenced in the MG Block Farm-in agreement.
- The Liberty LNG regassification project is on budget and moving forward with submission of a construction permit planned for July of this year. The Company continues to review joint venture opportunities related to this project.
- Canadian Superior has engaged Parkman Whaling, Alpha Petroleum Services and Ryder Scott for specific support services in Trinidad and Tunisia.
Business Overview and Future Strategy
With the Company exiting CCAA in September 2009, constituting a new board, negotiating a new banking arrangement and completing the Private Placement in January 2010, the Company is focused on the maximization of long-term sustainable value to the shareholders by:
- Hiring a Chief Executive Officer with the skills and strategic vision to extract value from the Company's assets while pursuing new areas of growth.
- Increasing the value of the Company's interests in Trinidad and Tobago, including a realistic and timely development plan for Block 5(c) with the Company's partner BG;.
- Appraisal, development and production of crude oil and natural gas from the 7th of November Block. Further, refining the various exploration prospects identified on the Block and seeking additional exploration and exploitation opportunities elsewhere in Tunisia and Libya.
- Developing the Western Canada asset base to increase average daily production along with replacement of producing reserves on an economic and cost effective basis by exploitation, full-cycle exploration and strategic acquisition. The Company is currently evaluating its entire acreage position in anticipation of an aggressive, multi-year drilling program commencing in the third quarter of 2010. Capital expenditures planned for the balance of 2010 will be approximately $25 million with near-term focus on the Drumheller and Kaybob core areas.
- Evaluating synergistic growth opportunities in North America focusing on both conventional and unconventional oil projects.
- Re-imaging the Company and continuing to build an ethical and transparent business culture.
Speaking today, Marvin M. Chronister, Canadian Superior's Chairman of the Board, said, "While the Company has been through a very difficult period during 2009, we believe it has emerged and continues to evolve as a much stronger company than it has ever been. We are aggressively pursuing our growth strategy and development of our assets. Therefore, we believe the best is still to come for our shareholders."
...
World Vaccine Congress Washington DC on 19th_–_22nd_of_April_2010
http://www.terrapinn.com/2010/wvcdc/confspon.stm
http://www.terrapinn.com/2010/wvcdc/programme.stm
http://www.terrapinn.com/2010/wvcdc/speakerList.stm
Encorium is present at World Vaccine Congress Washington DC on 19th – 22nd of April 2010.
Please visit our Vaccine page at: www.encorium.com/vaccines
http://www.terrapinn.com/2010/wvcdc/index.stm
Gold Sponsor: i.e. ENCORIUM
http://www.terrapinn.com/2010/wvcdc/confspon.stm
Speakers
http://www.terrapinn.com/2010/wvcdc/speakerList.stm
... Dr George Lautscham,
Director Business Development, Encorium
Zoom Technologies to Report Four Quarter and Full Year 2009 Financial Results
Date : 03/29/2010 @ 5:34PM
Source : MarketWire
Stock : Zoom Technologies (ZOOM)
http://ih.advfn.com/p.php?pid=nmona&cb=1269927367&article=42174831&symbol=N^ZOOM
Zoom Technologies to Report Four Quarter and Full Year 2009 Financial Results
BEIJING -- (Marketwire)
03/29/10
Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading China based manufacturer of mobile phones and other mobile electronic products, today announced it will release fourth quarter and full year 2009 financial results for the period ended December 31, 2009 after the market closes on Tuesday, March 30, 2010.
A conference call to review the results will begin at 5:00 p.m. US Eastern Time on March 30 (5:00 a.m. China Time, on Wednesday, March 31, 2010). The earnings call will be hosted by Chief Financial Officer, Anthony Chan.
The dial-in numbers are +1-877-407-9039 for US domestic callers and +1-201-689-8470 for international callers. A telephonic replay of the call will be available through April 14, 2010. The replay dial-in numbers are +1-877-660-6853 for US domestic callers and +1-201-612-7415 for international callers. The account number to access the replay is 3055 and the conference ID number is 348255.
About Zoom Technologies
Zoom Technologies is a holding company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for 3rd generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies' subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the brand name of Leimone. The company's products are both exported and sold domestically.
Zoom Technologies to Report Four Quarter and Full Year 2009 Financial Results
Date : 03/29/2010 @ 5:34PM
Source : MarketWire
Stock : Zoom Technologies (ZOOM)
http://ih.advfn.com/p.php?pid=nmona&cb=1269927367&article=42174831&symbol=N^ZOOM
Zoom Technologies to Report Four Quarter and Full Year 2009 Financial Results
BEIJING -- (Marketwire)
03/29/10
Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading China based manufacturer of mobile phones and other mobile electronic products, today announced it will release fourth quarter and full year 2009 financial results for the period ended December 31, 2009 after the market closes on Tuesday, March 30, 2010.
A conference call to review the results will begin at 5:00 p.m. US Eastern Time on March 30 (5:00 a.m. China Time, on Wednesday, March 31, 2010). The earnings call will be hosted by Chief Financial Officer, Anthony Chan.
The dial-in numbers are +1-877-407-9039 for US domestic callers and +1-201-689-8470 for international callers. A telephonic replay of the call will be available through April 14, 2010. The replay dial-in numbers are +1-877-660-6853 for US domestic callers and +1-201-612-7415 for international callers. The account number to access the replay is 3055 and the conference ID number is 348255.
About Zoom Technologies
Zoom Technologies is a holding company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for 3rd generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies' subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the brand name of Leimone. The company's products are both exported and sold domestically.
NexMed Files Investigational New Drug Application with FDA for Cancer Drug Candidate
Date : 03/29/2010 @ 11:06AM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1269875217&article=42168793&symbol=N^NEXM
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
PrevOnco (the anti-ulcer compound, lansoprazole, approved under the name Prevacid® and marketed in the U.S. by Takeda Pharmaceuticals North America, Inc.) had been under development by FasTrack Pharmaceuticals, Inc. for the treatment of solid tumors, in particular, for the treatment of HCC. FasTrack received orphan Drug status for PrevOnco from the FDA in August 2008. In vitro and in vivo pre-clinical data generated to date has demonstrated the ability of lansoprazole to inhibit tumor cell growth and enhance survival in mouse models of cancer alone, and in combination with doxorubicin.
NexMed recently acquired PrevOnco from San Diego-based FasTrack Pharmaceuticals, which was spun out of Bio-Quant in October 2009; NexMed acquired Bio-Quant in December 2009. As an upfront payment, NexMed paid approximately $205,000 in the form of the cancellation of indebtedness owed by FasTrack to Bio-Quant. In addition, FasTrack and NexMed will share equally in any future revenues, including payments received from potential licensing partners, after first deducting NexMed’s future development expenses, including a 15% premium.
NexMed’s prospective, open label, single-arm, multicenter Phase II trial will assess the safety and efficacy of lansoprazole and doxorubicin in patients with advanced unresectable HCC at up to 10 study sites throughout the U.S. The primary objective of the study is to assess the response rate to doxorubicin and lansoprazole. Subjects will be treated with oral lansoprazole 90mg twice daily and intravenous (IV) doxorubicin 60 mg/m2 administered every 21 days. Subjects will continue to receive IV doxorubicin plus lansoprazole, if tolerated, up to a maximum of six consecutive cycles of doxorubicin, as long as there is no evidence of progressive disease. A total of between 15 and 70 subjects are expected to be enrolled in the study for a period of up to 12 months in the absence of disease progression or intolerance. Total study duration is anticipated to be one to three years, depending on the rate of enrollment and number of patients enrolled.
Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “Acquiring the rights to PrevOnco represents NexMed’s entrance into oncology and adds an important product candidate to our pipeline. With a solid safety profile, generated from over 15 years of human use of lansoprazol for the treatment of ulcers, and early indications of anti-cancer activity observed in pre-clinical studies, we believe that PrevOnco is a strong candidate for development with NexMed’s proprietary NexACT drug delivery technology as a second generation compound. Our recent filing of the IND with the FDA is a major milestone for NexMed, and we look forward to initiation of the Phase II trial.”
Dr. Ziad Mirza, Chief Executive Officer of FasTrack, stated, “We are excited to partner our company’s lead product candidate with NexMed. The expertise of Dr. Damaj and his team in the field of oncology will be invaluable in taking this program to the next level and we look forward to starting the pending Phase 2 trials.”
About Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world, with a higher incidence in China and other Asian countries. Although uncommon in the U.S., there are a reported 8,500 to 11,000 new cases diagnosed each year, comprising 2% of all malignancies. Cases in the U.S. occur primarily in men of Chinese descent, a subpopulation which has a relatively high incidence of viral hepatitis – a known risk factor for HCC.
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.
About FasTrack Pharmaceuticals, Inc.
Based in San Diego, CA and founded in 2009, FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs to treat life threatening diseases, including cancer and autoimmune diseases. The Company’s lead product candidate, PrevOnco, is under development for the treatment of various solid tumors.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including, but not limited to, the ability to successfully launch and complete the planned PrevOnco Phase II trial and the ability to reproduce pre-clinical findings in clinical trials.
NexMed Files Investigational New Drug Application with FDA for Cancer Drug Candidate
Date : 03/29/2010 @ 11:06AM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&cb=1269875217&article=42168793&symbol=N^NEXM
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
PrevOnco (the anti-ulcer compound, lansoprazole, approved under the name Prevacid® and marketed in the U.S. by Takeda Pharmaceuticals North America, Inc.) had been under development by FasTrack Pharmaceuticals, Inc. for the treatment of solid tumors, in particular, for the treatment of HCC. FasTrack received orphan Drug status for PrevOnco from the FDA in August 2008. In vitro and in vivo pre-clinical data generated to date has demonstrated the ability of lansoprazole to inhibit tumor cell growth and enhance survival in mouse models of cancer alone, and in combination with doxorubicin.
NexMed recently acquired PrevOnco from San Diego-based FasTrack Pharmaceuticals, which was spun out of Bio-Quant in October 2009; NexMed acquired Bio-Quant in December 2009. As an upfront payment, NexMed paid approximately $205,000 in the form of the cancellation of indebtedness owed by FasTrack to Bio-Quant. In addition, FasTrack and NexMed will share equally in any future revenues, including payments received from potential licensing partners, after first deducting NexMed’s future development expenses, including a 15% premium.
NexMed’s prospective, open label, single-arm, multicenter Phase II trial will assess the safety and efficacy of lansoprazole and doxorubicin in patients with advanced unresectable HCC at up to 10 study sites throughout the U.S. The primary objective of the study is to assess the response rate to doxorubicin and lansoprazole. Subjects will be treated with oral lansoprazole 90mg twice daily and intravenous (IV) doxorubicin 60 mg/m2 administered every 21 days. Subjects will continue to receive IV doxorubicin plus lansoprazole, if tolerated, up to a maximum of six consecutive cycles of doxorubicin, as long as there is no evidence of progressive disease. A total of between 15 and 70 subjects are expected to be enrolled in the study for a period of up to 12 months in the absence of disease progression or intolerance. Total study duration is anticipated to be one to three years, depending on the rate of enrollment and number of patients enrolled.
Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “Acquiring the rights to PrevOnco represents NexMed’s entrance into oncology and adds an important product candidate to our pipeline. With a solid safety profile, generated from over 15 years of human use of lansoprazol for the treatment of ulcers, and early indications of anti-cancer activity observed in pre-clinical studies, we believe that PrevOnco is a strong candidate for development with NexMed’s proprietary NexACT drug delivery technology as a second generation compound. Our recent filing of the IND with the FDA is a major milestone for NexMed, and we look forward to initiation of the Phase II trial.”
Dr. Ziad Mirza, Chief Executive Officer of FasTrack, stated, “We are excited to partner our company’s lead product candidate with NexMed. The expertise of Dr. Damaj and his team in the field of oncology will be invaluable in taking this program to the next level and we look forward to starting the pending Phase 2 trials.”
About Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world, with a higher incidence in China and other Asian countries. Although uncommon in the U.S., there are a reported 8,500 to 11,000 new cases diagnosed each year, comprising 2% of all malignancies. Cases in the U.S. occur primarily in men of Chinese descent, a subpopulation which has a relatively high incidence of viral hepatitis – a known risk factor for HCC.
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer.
About FasTrack Pharmaceuticals, Inc.
Based in San Diego, CA and founded in 2009, FasTrack Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutic drugs to treat life threatening diseases, including cancer and autoimmune diseases. The Company’s lead product candidate, PrevOnco, is under development for the treatment of various solid tumors.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including, but not limited to, the ability to successfully launch and complete the planned PrevOnco Phase II trial and the ability to reproduce pre-clinical findings in clinical trials.
Global Erectile Dysfunction Drugs Market to Reach $4.4 Billion by 2015, According to New Report by Global Industry Analysts, Inc
March 24, 2010
http://www.prweb.com/releases/2010/03/prweb3735144.htm
GIA announces the release of a comprehensive global report on Erectile Dysfunction Drugs markets. The world market for erectile dysfunction drugs is projected to reach $4.4 billion by the year 2015. This is primarily driven by a rapid rise in the number of patients suffering from erectile dysfunction, and aging population. Further, advancements in technology, and a better understanding of the physiological and psychological causes of ED are enabling to develop advanced treatments and drive market growth for erectile dysfunction drugs.
San Jose, CA (PRWEB) March 24, 2010 -- Erectile Dysfunction (ED) is condition in which a man is not able to achieve and maintain adequate erection for a satisfactory sexual intercourse. It affects the lives of many middle-aged men as well as their partners across the world. Erectile dysfunction can also be a sign of an emotional or physical problem that needs treatment. Earlier, ED was considered a taboo subject and a very small percentage of men would actively seek treatment. However, over a period of time, more men have started seeking help. Moreover, doctors are gaining a better understanding of the physiological and psychological causes of ED, which is enabling them to develop advanced treatments.
The United States and Europe dominate the world erectile dysfunction drugs market as stated by the new market research report on erectile dysfunction drugs market. With a rise in the dependence on medicines that causes side effects such as erectile dysfunction, increase in the baby-boomer population, and various other co-morbid groups including depression, diabetic, and cardiovascular patients, the US market for erectile dysfunction drugs witnessed a significant expansion. These numbers are expected to experience continuous growth in the country, paving way for a higher demand as well as steady revenues. Due to the convenience and effectiveness associated with the prescription oral medications, they continue to remain the most common form of treatment for erectile dysfunction in Europe. The launch of novel topical, over-the-counter and prescription drugs would benefit in expanding the ED market, as well as paving way for the development of advanced oral ED medications.
Erectile Dysfunction Drugs: A Global Strategic Business Report
There are several companies involved in the development of therapeutics for the treatment of ED. While the treatment options differ between oral therapies, implants, injectibles, and topical treatments, oral medications continue to dominate the ED drug market worldwide. Key players profiled in the report include Abbott Laboratories, Eli Lilly and Company Inc., F. Hoffmann-La Roche Inc., GlaxoSmithKline plc, Nexmed Inc., Pfizer Inc., Sanofi-aventis SA, Vivus Inc., and Warner Chilcott Limited.
The report titled "Erectile Dysfunction Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, product overview, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Canada, Japan, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Erectile_Dysfunction_Drugs_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/
http://www.cordblood-america.com/3-8-2010%20investor%20profile.pdf
January 6, 2009 – Launched social media campaign to start the
conversation about stem cells. Around this time, we also stated
our mission for 2009. We said Cord Blood America, Inc. is
focused on three key pillars of success for 2009: Organic growth,
acquisitions and debt reduction leading to a healthy balance
sheet
February 9, 2009 – After the current administration announced
its plan and support of stem cell research in the United States,
Cord Blood America is listed on the ETF Innovators Stem Cell
index.
February 12, 2009 – CBAI announces $1M reduction in long
term debt.
February 25, 2009 – CBAI announces a restructuring of long
term debt to free up cash flow for the company.
March 5, 2009 – CBAI was noted as the top stock performer on
ETF Innovators Stem Cell index.
April 5, 2009 – After Congress introduced legislation to promote
family banking of Cord Blood stem cells, CBAI announced its
total long term debt reduction was now $1.75M.
April 9, 2009 – CBAI announced its first customer in Germany,
noting its dedication to organic growth.
April 23, 2009 – CBAI announces additional debt reduction of
$817,000.
May 7, 2009 – CBAI announced it will acquire or build its own
stem cell processing and storage laboratory, eliminating the need
to outsource lab services and projecting a tremendous increase in
gross profit once complete.
May 14, 2009 – CBAI announces it received a $2.3M commitment
to finance the building of the stem cell lab.
May 27, 2009 – CBAI announces debt has been reduced by
$4.194M in 2009.
June 11, 2009 – CBAI announces additional expansion in
Europe.
June 22, 2009 – CBAI announces contracting independent
affiliate to sell services in Caribbean and Central America.
July 7, 2009 – CBAI secures $7.5M in long term equity financing
for growth and acquisition opportunities.
July 9, 2009 – CBAI announces it has begun building the largest
stem cell lab in Nevada and one of the largest in the US.
July 10, 2009 – CBAI announces hiring of key management team
to lead the scientific team of the new lab.
August 13, 2009 – Announces Key Agreement with MyHealth Mart
ValueAdded Discount Program for members of Blue Cross of
Northeastern Pennsylvania.
August 24, 2009 – Announces another 1.6M in debt reduction,
totaling $6.6M for 2009.
September 10, 2009 – Cord Blood America nearing completion of
construction of Las Vegas laboratory; one of the largest cryogenic
labs in U.S.
September 28, 2009 – Cord Blood America opens Las Vegas
Cryogenic Laboratory; consolidates offices in Nevada
October 2, 2009 – Cord Blood America retires note in continuing
effort to reduce debt
October 5, 2009 – Cord Blood America continues to reduce debt;
three notes retired
October 7, 2009 – Cord Blood America announces debt reduction
tally: $8.7 Million in 2009; $3.7 Million in third quarter
October 15, 2009 – Cord Blood America details Las Vegas laboratory
progress in analyst interview
November 6, 2009 – Cord Blood America updates advantages of Las
Vegas Laboratory in analyst interview; explains recent S1 filing
November 16, 2009 – Cord Blood America announces debt down;
gross margins up; balance sheet significantly improved
December 8, 2009 – Cord Blood America announces Grand Opening
of lab, corporate offices on January 22, 2010
December 16, 2009 – Cord Blood America says 2009 debt reduction
tops $10 Million
January 4, 2010 – Cord Blood America announces cord blood stem
cell processing and storage agreement with BioCells, a South
American company
January 6, 2010 – Cord Blood America announces $1.35 Million note
retired
January 11, 2010 – Cord Blood America completes financings for
2010 acquisition, growth strategy
January 13, 2010 – Cord Blood America Sets Business Strategy for a
Successful 2010
January 15, 2010 – Cord Blood America announces schedule for
Grand Opening of laboratory on January 22, 2010
January 19, 2010 – Cord Blood America contracts with Center for
Stem Cell Awareness to sell collection and storage services in Florida
January, 21, 2010 – Cord Blood America Announces contract with
BioE, provides clients highest quality, ‘State of the Art’ processing
system for cord blood storage
January 26, 2010 – Cord Blood America announces $6 Million in
notes retired
February 8, 2010 – Cord Blood America finalizes cord blood stem cell
processing and storage agreement with BioCells, a Major South
American Company
February 26, 2010 – Cord Blood America Names Shamoon Ahmad,
M.D., Director of Its Medical Advisory Board
January 11, 2010 – Cord Blood America completes financings for
2010 acquisition, growth strategy
http://www.cordblood-america.com/3-8-2010%20investor%20profile.pdf
How did they purchase the German Co.Did they issue them stock or cash.I can't imagine any more shares being issued,I'd say we are diluted to the max.That's what I believe is holding the share price back.
WaMu: JP Morgan Keeps Turning Lead Into Gold
March 28, 2010
http://seekingalpha.com/article/195908-wamu-jp-morgan-keeps-turning-lead-into-gold?source=feed
Capitol Hill’s favorite banker keeps turning lead into gold.
Late Friday JP Morgan (JPM) signed a settlement offer with Washington Mutual's (WAMUQ.PK) bankrupt holding company that will, in essence, pay JP Morgan to purchase it.
In September 2008, JP Morgan paid the FDIC $1.9 billion for the 200 year old thrift which, according to its last annual filing, boasted $323 billion in assets and over 2,200 branches. Immediately after being seized WaMu's holding company declared bankruptcy and journeyed to court in order to fight over assets in which to pay creditors.
In its early chapter eleven filings WaMu’s parent company listed over $32 billion in assets and $8 billion in liabilities. Unfortunately most of those assets never materialized. Now after eighteen months of legal wrangling, WaMu's bondholders have decided to throw in the towel.
In the settlement offer WaMu will relinquish all claims against JP Morgan and the FDIC. In return WaMu will be allowed to keep a $3.9 billion dollar deposit it held in its own bank. Most of the $3.9 billion deposit was generated from the sale of preferred securities in 2006 and 2007. Additionally WaMu will be allowed to keep $1.8 to $2.0 billion of its own tax return created from huge losses in 2008. The rest of the projected $5.6 billion return will be split between the FDIC and JP Morgan.
According to the settlement terms JP Morgan will receive $5 billion in HELOC backed securities valued on the open market at 60% of par, $193 million in Visa class B securities, $2.1 billion in cash, and a $20 million wind farm, all from WaMu. Given the initial purchase price of WaMu for $1.9 billion in 2008, these additional assets received means that JP Morgan will pay a negative $3.4 billion for their purchase of the bank.
The loss of these assets will heavily impact WaMu's balance sheet which now stands to make only the bondholders whole, according to the settlement's disclosure statement. Currently senior WaMu holding company debt trades at 106 cents on the dollar.
Under the terms of the settlement WaMu shareholders will receive nothing.
In the disclosure statement WaMu's attorneys stated that the proposed settlement will net the most for all creditors and that further legal dispute would only financially harm the estate. This comes in stark contrast to prior statements by WaMu's equity counsel that a protracted legal battle with JP Morgan and the FDIC may have returned up to $20 billion to the estate.
Currently the settlement is awaiting the approval of the FDIC, Washington Mutual bank bondholders, WaMu unsecured creditors, WaMu preferred shareholders, and the bankruptcy judge. An incomplete plan of reorganization was also filed on Friday along with the disclosure statement. The incomplete POR lacks a balance sheet meaning that WaMu’s unsecured creditors are left only to guess at what they may eventually recover, if anything.
Despite the negative purchase price, Jamie Dimon, CEO of JP Morgan has indicated that the purchase of WaMu could have been closed for less, much less. In July 2009 he stated that JP Morgan “could have bought WaMu for a dollar” because of the projected losses that would have been taken on the deal.
The losses never materialized. In May 2009, JP Morgan wrote up its WaMu loan portfolio by $25 billion.
Had the $1 purchase price gone through JP Morgan would have eventually been paid $5.1 billion by WaMu and the FDIC to assume the bank.
While the deal may be good for JP Morgan, former WaMu customers are not so fortunate. Nationally many WaMu Providian credit card customers have since experienced dramatic rate increases. In Oregon, WaMu checking clients report that deposits are being held for fourteen days prior to being accredited to accounts. This abnormally long waiting period means that many checking customers are now being hit by multiple $35-a-peice overdraft charges for having insufficient funds. In northern California, out-the-door waiting lines for teller service at one branch sparked verbal outrage and multiple client threats to move deposits to a community bank branch. The branch responded after twenty minutes by temporarily adding a teller.
Meanwhile FDIC chairwoman Sheila Bair is continuing to push for additional powers that would allow the FDIC to not only shutter banks but their holding companies. This authority would allow for the FDIC to avoid future conflicts when it closes a bank but is unable to force a holding company to capitulate, as is in the case with WaMu. It has come under scrutiny after internal JP Morgan e-mails and PowerPoint presentations revealed that as early as March 2008 regulators were in negotiations with JP Morgan on the closure of Washington Mutual, termed “Project West”, six months prior to the bank’s seizure.
Welcome to Chase. Better banking.
Q4 2009 Keryx Biopharmaceuticals, Inc. Earnings Conference Call (Replay)
03/25/10 at 8:30 a.m. ET
http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-irhome
January 11, 2010 – Cord Blood America completes financings for
2010 acquisition, growth strategy
http://www.cordblood-america.com/3-8-2010%20investor%20profile.pdf
One question that runs through my mind do you think Matt put the carriage before the horse and put out the report about aquiring the German Company then paid for the 51% through the rise in PPS meaning selling from yesterday's gains?
Might seem not likely but very ballsy if he did
Coming Next Week: Updates on ..., NWCI and More
Written by Staff and Wire Reports
Friday, 26 March 2010 06:18
http://biomedreports.com/articles/most-popular/34086-coming-next-week-updates-on-mbtg-nwci-and-more.html
Also next week, we'll have an update on NewCardio, Inc. (NWCI.OB). This is a company we've been watching closely in anticipation of a partnership development and our sources tell us that the company may have additional news regarding revenue generating contracts in the coming days. NewCardio, Inc., a development-stage cardiac diagnostic company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease, as well as for the cardiac safety assessment of drugs under development. The company?s technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram(ECG) electrodes. Its developing products include QTinno, a phase I trial product, which is an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a diagnostic center that receives, processes, and analyzes the data.
Short Interest
http://www.shortsqueeze.com/?symbol=emkr&submit=Short+Quote%99
Short Interest (Shares Short)
8,656,700
Days To Cover (Short Interest Ratio)
14.9
Short Percent of Float
11.31 %
Record Date
2010-MarB
...a conference call on Tuesday, March 30 at 2:00 p.m
... once again:
http://ih.advfn.com/p.php?pid=nmona&cb=1269603246&article=42116847&symbol=NB^CBAI
Mr. Schissler said the acquisition was financed through monies previously raised and targeted specifically for acquisitions.
...pure manipulation @ NITE and ETMM
The Hartford to Webcast Investor Presentation on April 1
Date : 03/25/2010 @ 12:15PM
Source : Business Wire
Stock : The Hartford Financial Services Group, Inc. (HIG)
http://ih.advfn.com/p.php?pid=nmona&cb=1269537301&article=42127259&symbol=NY^HIG
The Hartford Financial Services Group, Inc. (NYSE: HIG) will host an investor presentation on Thursday, April 1 from 9:00 a.m. – 11:45 a.m. EDT in New York City. The presentation will be simultaneously webcast and available on the company’s website at http://ir.thehartford.com, with replays of the sessions available following the event.
At the presentation, The Hartford’s Chairman, President and Chief Executive Officer Liam E. McGee and Executive Vice President and Chief Financial Officer Christopher J. Swift, will discuss The Hartford’s business, capital and financial outlook, which will be followed by a question and answer session.
The planned agenda for the presentation is as follows:
9 a.m. Liam E. McGee Remarks 10 a.m. Christopher J. Swift Remarks 10:30 a.m. Break 10:45 a.m. Q&A and Closing Comments
About The Hartford
Celebrating nearly 200 years, The Hartford (NYSE: HIG) is an insurance-based financial services company that serves households, businesses and employees by helping to protect their assets and income from risks, and by managing wealth and retirement needs. A Fortune 500 company, The Hartford is recognized widely for its service expertise and as one of the world’s most ethical companies. More information on the company and its financial performance is available at www.thehartford.com.
HIG-F
Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our Quarterly Reports on Form 10-Q, our 2009 Annual Report on Form 10-K and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued.
Apr 12-15, 2010
Las Vegas Convention Center
Las Vegas, NV
http://www.emcore.com/news_events
FORM 4
Statement of Changes in Beneficial Ownership (4)
Date : 03/24/2010 @ 5:31PM
Source : Edgar (US Regulatory)
Stock : (EMKR)
http://ih.advfn.com/p.php?pid=nmona&cb=1269536294&article=42113048&symbol=N^EMKR
Dow Could Hit 14K Before Next Crash, Says Phil Town
Posted Mar 25, 2010 09:15am EDT
by Peter Gorenstein
http://finance.yahoo.com/tech-ticker/dow-could-hit-14000-before-next-crash-says-phil-town-449487.html?tickers=apol,dv,esi,^dji,dia,spy,^gspc&sec=topStories&pos=9&asset=&ccode=
"I can see this market at 14,000," says investor and author Phil Town. Using the secular bear market of the 1970s as his road-map, Town thinks the market might continue its upward swing and then crash once again, continuing the boom bust cycle of the last ten years.
Town's investment strategy won't change either way. It is "not about guessing the market right," he tells Aaron in the accompanying clip.
Town doesn't look at the broad indexes as a guide. And, neither should you, if you want to get rich, he recommends. "If you want to be a great investor and really start taking control of your finances I think you have to start looking for individual companies," says the author of Payback Time.
Bull or bear market, Town believes there's always undervalued companies that make good investments. He suggests finding a few businesses one can understand really well and then investing accordingly.
He's currently looking at several education-related stocks, in the belief higher education is a winning investment as long as unemployment remains above normal. He specifically mentioned ITT Educational Services, Apollo Group and Devry.
(Disclosure: He does not currently own shares in any of these above mentioned stocks.)
Novelos Therapeutics Enrolls 1st Patient in Phase 2 Hepatitis C Trial with NOV-205
Date : 03/25/2010 @ 8:30AM
Source : Business Wire
Stock : Novelos Therapeutics, Inc. (NVLT)
http://ih.advfn.com/p.php?pid=nmona&cb=1269520641&article=42121672&symbol=NB^NVLT
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin. Details of the trial design may be found on www.clinicaltrials.gov – ID: NCT01058512, or via a link at www.novelos.com ‘Clinical Trials’ section.
“The safety data from the U.S. Phase 1b short-term dosing trial support initiation of this Phase 2 trial, evaluating both dose escalation and extended dosing with NOV-205. Because NOV-205 is not a direct anti-viral agent, we believe the Phase 2 trial is more likely to demonstrate clinical activity,” said Dr. Raymond Koff, Novelos’ expert Medical Advisor for hepatitis. “We look forward to further evaluating the clinical activity of NOV-205 in chronic hepatitis C non-responders – a large patient population for which there is no established, beneficial therapy.”
About Hepatitis C
The World Health Organization estimates that chronic hepatitis C affects 170 million people worldwide. In the U.S., according to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million persons are affected. Chronic infection can progress to cirrhosis, end-stage liver disease and hepatocellular carcinoma. While there are varying estimates about the size of the global market for hepatitis C drugs, the current global market is believed to be in excess of $3 billion per year. Currently about 8,000-10,000 hepatitis C-related deaths occur annually in the U.S. and this could double over the next 10 to 20 years. The current standard-of-care drugs for chronic hepatitis C – the combination of pegylated interferon and ribavirin – are expensive, have significant toxicities, are difficult to tolerate for many patients and have limited long-term efficacy in genotype 1 patients (the most common HCV genotype seen in the U.S. and much of the world). Approximately 50% of the genotype 1 patients do not benefit from treatment with pegylated interferon plus ribavirin, and currently there is no approved standard of care to treat these non-responding chronic hepatitis C patients.
About NOV-205 for Hepatitis
NOV-205 is a unique, injectable, small-molecule proprietary formulation of oxidized glutathione and inosine that acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. A U.S. Phase 1b trial in chronic hepatitis C patients who previously failed treatment with pegylated interferon plus ribavirin was successfully concluded based on demonstration of a favorable safety profile. Previously, NOV-205 demonstrated clinical activity (reduced viral load and improved liver function) and safety as monotherapy for treatment of hepatitis B and C in a total of 178 patients from Russia. The ongoing U.S. Phase 2 trial aims to expand the safety database for NOV-205 and assess its effects on the same efficacy-related endpoints using a comparable dosing regimen, although this trial is being conducted in a more difficult to treat interferon/ribavirin non-responder patient population.
About Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. Novelos is seeking to build a pipeline through licensing or acquiring clinical stage compounds or technologies for oncology indications. Our lead compound, NOV-002, has been administered to approximately 1,000 cancer patients in clinical trials and is in Phase 2 development for solid tumors in combination with chemotherapy. Novelos has a partnership with Mundipharma, an independent associated company of Purdue Pharma, to develop and commercialize NOV-002 in Europe and Asia (excluding China). Novelos’ second compound, NOV-205, which has been administered to approximately 200 hepatitis patients in clinical trials, is in Phase 2 development for chronic hepatitis C non-responders. Both compounds have been partnered with Lee’s Pharm in China. For additional information about Novelos please visit www.novelos.com
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.
WEBPAGE: Stellacure GmbH
http://www.stellacure.com/index.php?navid=1
Partners -
http://www.zoomleimone.com/html/friend.htm
Customer
Customer Profile (Using an exchange rate of 1 USD = 6.8387 CNY)
MOTOROLA
Established Strategic Partnership in June 2000, mainly providing cell phones and radiophones, accumulated revenues over US $175,000,000. 2002 Motorola Global Elite Suppliers
SAMSUNG
Established Strategic Partnership in April 2006, mainly providing digital camera mounting, accumulated revenues over US $2,200,000.
DANAHER MOTION
Established Strategic Partnership in March 2007, mainly providing various driving controller manufacturing for Danaher global companies, accumulated revenues over US $5,000,000.
SIMCOM
Established Strategic Partnership in Nov 2003, mainly providing wireless modules and cell phones, accumulated revenues over US $73,000,000. 2004 and 2005 Simcom Elite Suppliers.
Beijing Tianyu
Established Strategic Partnership in May 2006, mainly providing cell phone manufacturing, accumulated revenues over US $14,500,000.
SPREADTRUM
Established Strategic Partnership in March 2007, mainly providing wireless modules manufacturing
CECT
Established Strategic Partnership in Dec 2003, mainly providing cell phone manufacturing, accumulated US $14,500,000.
Earnings Announcements for Wednesday, March 24
http://biz.yahoo.com/research/earncal/z/zoom.html
Zoom Technologies to Enter China New Media Arena Through Leimone Culture Deal With China Central Television
Date : 03/24/2010 @ 8:31AM
Source : MarketWire
Stock : Zoom Technologies (ZOOM)
http://ih.advfn.com/p.php?pid=nmona&cb=1269451690&article=42102939&symbol=N^ZOOM
Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading China-based manufacturer of mobile phones and other mobile electronic products, today announced that the Company's previously disclosed acquisition target, Beijing Leimone Shengtong Culture Development Company (Leimone Culture), has signed an agreement with China Central Television (CCTV), the major state television broadcaster in China, with 19 channels broadcasting to more than one billion viewers. According to the agreement, Leimone Culture will provide approved media content to CCTV's mobile users and will bundle CCTV.com's mobile TV access link onto Zoom's branded "Leimone" mobile phones and onto Zoom Original Equipment Manufacturer (OEM) customers' phones.
Pursuant to Section 1.3 of the Share Exchange Agreement dated January 28, 2009 between Zoom, Gold Lion Holding Ltd and Mr. Lei Gu, which shareholders of Zoom approved on September 8, 2009, Zoom has the option of purchasing Mr. Gu's shares of a list of companies controlled by him, and among these companies is Leimone Culture of which Mr. Gu owned 70% in September 2009. On December 1, 2009, Zoom's board of directors approved to pursue the acquisition of 100% of Leimone Culture subject to further due diligence, with details of the transaction to be finalized in the first half of 2010.
Mr. Leo Gu, Chairman and CEO of Zoom Technologies, commented, "This agreement with CCTV is the first of its kind for mobile media services, and is a milestone for Leimone Culture and Zoom Technologies. It partners Zoom through Leimone Culture with the largest media company in China, and positions us to benefit from the outstanding growth expected in the business of delivering video programs to mobile phones. We expect our mobile media business to grow significantly once Zoom completes the acquisition of Leimone Culture later this year. China's continuing economic growth and the strength of our manufacturing business also give us confidence in achieving significant growth."
CCTV currently captures 60% of China's mobile media services, making CCTV the largest program provider of "new media" for the mobile handset. Leimone Culture is the first company officially contracted by CCTV to participate with CCTV in this new mobile media service. Leimone Culture will generate revenue based on viewership of media programs supplied by Leimone Culture onto CCTV's mobile TV program access link. Leimone Culture has been selected as CCTV's supplier for a number of reasons, including content quality and Zoom's manufacturing capabilities, which can bundle the CCTV mobile TV access link in up to 10 million mobile phones in 2010.
Zoom expects to finalize the acquisition of Leimone Culture by mid-year 2010.
Leimone Culture has been a provider of mobile video services to China's top tier mobile phone service providers, including China Mobile since 2005 and China Unicom since 2007. Since the advent of 3G in China in mid-2009, Leimone Culture has captured revenues from advertisements loaded onto new phones, value-added applications provided to the mobile operators, the production of mobile short films, and web-based ad sales.
About Zoom Technologies
Zoom Technologies is a holding company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for 3rd generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies' subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the brand name of Leimone. The company's products are both exported and sold domestically.
Forward-Looking Statements
Certain statements in this press release may constitute "forward looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events, including the acquisition of Leimone, which may require shareholder approval which cannot be assured. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Zoom Factsheet
http://www.zoomleimone.com/resources/Zoom%203Q09%20Factsheet%202009Dec.pdf
ABOUT ZOOM TECHNOLOGIES
Zoom Technologies is a well established high-tech enterprise in electronic and telecommunication product design, development, processing and
manufacturing for 3rd generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies’ subsidiary,
Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for
Original Equipment Manufacturer (OEM) customers such as Samsung and K-Touch, the largest domestic brand in China surpassing Motorola, Sony
Ericsson, and LG, and also designs and manufactures its own brand of mobile phones under the Leimone brand. Zoom is ranked among the top 10
Chinese mobile phone manufacturers in capacity with over 1,400 employees.
POSITIONED FOR GROWTH
• Identified a niche market and focuses on developing mid to high-end, feature-rich, customized phones at a competitive prices
• Effectively leverage manufacturing and R&D capabilities and strong government connection.
• Focus on distribution to municipal level agents in tier 3 and tier 4 cities to utilize their extensive networks to sell products
• Collaborate with major telecoms to introduce bundled phones, which we believe is more economical and convenient to customers
• 204% revenue growth year over year and next income expected to exceed $6 million in 2009
RECENT CORPORATE HIGHLIGHTS
• Third quarter 2009 revenue increased 204% year over year to $55.29 million
• Third quarter net income increased 138% year over year to $1.73 million
• Full year 2009 revenue guidance increased to between $185 and $195 million from $145 to $155
million
• Full year 2010 net income guidance in the range of $10.75 to $11.25 million on adjusted basis
• Continued listing on Nasdaq, under ticker “ZOOM” following share exchange with Gold Lion Holdings Ltd.
• Entered into an agreement with China Telecom to distribute LEIMONE mobile phones
CHINA’S MOBILE PHONE MARKET
• Largest mobile phone subscriber base in the world with 641 million subscribers in 2008. The figure is expected to grow at a CAGR of 17.7%
through 2010, reaching 893 million.
• Mobile phone penetration rate is only 47% as compared to over 90% or even over 100% in many developed and developing countries -- Huge
untapped market in the 3rd tier and 4th tier cities.
• 3G network commercialization will drive subscriber demand for feature-rich, customized mobile phones with new applications and large volume
data transmission.
• Global sales of feature-rich smart phones expected to increase from 9 million units in 2003 to 418 million units in 2010; percentage of total
mobile handsets sales expected to increase from 1.7% to 33% during the same period.
Canadian Superior Energy Inc. Announces Shareholder Conference Call
Mar 24, 2010 11:16 ET
http://www.marketwire.com/press-release/Canadian-Superior-Energy-Inc-Announces-Shareholder-Conference-Call-TSX-SNG-1137243.htm
CALGARY, ALBERTA--(Marketwire - March 24, 2010) - Canadian Superior Energy Inc. ("Canadian Superior" or the "Company") (TSX:SNG) (NYSE Amex:SNG) will host a conference call on Tuesday, March 30 at 2:00 p.m. MST to provide an update on exploration and corporate activities. Mr. Marvin Chronister, Chairman of the Board, Robb Thompson, Chief Financial Officer and Leif Snethun, Chief Operating Officer will jointly host the call.
All interested parties can join the call by dialing (416) 340-8527 or (877) 240-9772. Please dial-in 15 minutes prior to the call to secure a line. The conference call will be archived for replay on our website within 48 hours of this conference call.
Canadian Superior Energy Inc. is a Calgary, Alberta, Canada based diversified global energy company engaged in the exploration and production of oil and natural gas and in the development of a liquefied natural gas ("LNG") project. Its operations are located in Western Canada, offshore Trinidad and Tobago, North Africa, offshore Eastern Canada, and offshore Eastern United States. See Canadian Superior's website at www.cansup.com to review further detail on Canadian Superior's operations.
For more information, please contact
Canadian Superior Energy Inc.
Investor Relations
(403) 294-1411
(403) 216-2374 (FAX)
or
Canadian Superior Energy Inc.
Suite 3200, 500 - 4th Avenue S.W.
Calgary, Alberta, Canada
T2P 2V6
www.cansup.com
Aeterna Zentaris books profit, revenue spike in fourth quarter
100324
http://ca.news.yahoo.com/s/capress/100324/business/aeterna_zentaris